



# Atypical Antipsychotics

*Iowa P&T Committee*

September 13, 2012

# Atypical Antipsychotics In Mental Health

- **High Level of Utilization Across Multiple Diagnoses**
  - Schizophrenia
  - Bipolar Disorder (manic and mixed)
  - Treatment of irritability and aggression associated with autism
  - Augmentation of antidepressants
  - Ongoing off-label use (e.g. anxiety, insomnia)

# Atypical Antipsychotics In Mental Health

- **National use has grown substantially, leading to several concerns**
  - Weight gain
  - Metabolic adverse effects (diabetes, elevated lipids)
  - Neurologic toxicity, cardiovascular adverse effects
- **Judicious Use – diagnostic accuracy in identification of underlying diagnosis and instituting appropriate treatment**
  - ADD/ADHD
  - Depression
  - Irritability


# Atypical Antipsychotics In Mental Health

- Radically different treatment effects at different doses
- Schizophrenia/Schizoaffective/Bipolar Disorder
  - Typically High Dose Use
- Major Depression Augmentation
  - Low Dose Use
    - Abilify®
    - Seroquel XR®

# Atypical Antipsychotics In Mental Health

- Differing rates of adverse events though similar efficacy in major mental illnesses, including Schizophrenia and Bipolar Disorder
- Amongst the most costly drug treatments for Medicaid
  - Currently accounts for roughly 13% of the drug spend
  - Most costly therapeutic category
- Rates of weight gain and metabolic adverse effects vary by agent
  - Clozapine, Olanzapine, Quetiapine/Risperidone, Iloperidone, Asenapine, Lurasidone, Ziprasidone, Aripiprazole
- In major mental illnesses, compliance is highly correlated with relapse rates

# Atypical Antipsychotics In Mental Health



# Atypical Antipsychotics In Mental Health

- PDL strategies for achieving maximal access in a cost effective manner
  - Pill splitting
  - Preferred placement of more cost-effective agents
    - more options now than ever before in this category
      - generics AND less costly brands

# Atypical Antipsychotics In Mental Health

- PDL designed to favor generics and more cost effective treatment options
  - Lack of response/poor tolerability of 2 preferred agents to include the generics (if more cost effective than brand)
  - Lurasidone (Latuda<sup>®</sup>), Asenapine (Saphris<sup>®</sup>), and Iloperidone (Fanapt<sup>®</sup>) are newer, more cost effective brand options to consider





## Questions?